CG Oncology (NASDAQ:CGON) Stock Price Down 6%

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) was down 6% during mid-day trading on Monday . The stock traded as low as $36.90 and last traded at $37.38. Approximately 105,254 shares were traded during trading, a decline of 84% from the average daily volume of 661,810 shares. The stock had previously closed at $39.75.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CGON shares. Cantor Fitzgerald started coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set an "overweight" rating and a $75.00 price target on the stock. The Goldman Sachs Group began coverage on CG Oncology in a report on Tuesday, February 20th. They set a "neutral" rating and a $42.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Thursday, April 4th. Finally, Morgan Stanley began coverage on CG Oncology in a report on Tuesday, February 20th. They set an "overweight" rating and a $55.00 price objective for the company.

CG Oncology Price Performance

The business has a fifty day moving average price of $41.35.

Insider Activity

In related news, CFO Corleen M. Roche purchased 2,000 shares of the stock in a transaction dated Monday, January 29th. The stock was bought at an average cost of $19.00 per share, with a total value of $38,000.00. Following the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $38,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other CG Oncology news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the purchase, the insider now owns 400,000 shares in the company, valued at $7,600,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Corleen M. Roche bought 2,000 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the purchase, the chief financial officer now owns 2,000 shares in the company, valued at approximately $38,000. The disclosure for this purchase can be found here. Insiders purchased a total of 666,472 shares of company stock valued at $12,662,968 in the last ninety days.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.